Despite the controversy about the expression of TGM4 in PCa, these previous studies combined with our findings may indicate a possible role of TGM4 as a tumor suppressor gene and, after a further validation in a larger cohort of patients, its potential use not only as a PCa diagnostic biomarker in urinary EVs, but also to identify the poor prognosis patients using biopsies or tissue samples from radical prostatectomy. This evidence concerns the gene TGM4 and posterior cortical atrophy.